- IntoCell Inc. has entered into a strategic collaboration with Xcellon Biologics, a U.S.-based CDMO, to integrate its proprietary OHPAS drug-linker platform into ADC development and manufacturing.
- The partnership combines IntoCell’s advanced payload-linker technologies with Xcellon’s bioconjugation and manufacturing expertise to accelerate ADC innovation for biotech and pharmaceutical partners.
IntoCell Inc., a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), has announced a strategic collaboration with Xcellon Biologics, a U.S.-based contract development and manufacturing organisation (CDMO) specialising in ADCs and complex biologics.
Under the agreement, IntoCell’s proprietary OHPAS drug-linker platform—featuring Duocarmycin and Nexatecan-based payloads—will be incorporated into Xcellon Biologics’ ADC development toolbox. Xcellon will provide bioconjugation, ADC development, and manufacturing services to support biotech and pharmaceutical clients using IntoCell’s technology in their programmes.
The collaboration aims to accelerate access to innovative ADC technologies by combining IntoCell’s chemistry expertise with Xcellon’s contract manufacturing infrastructure in the United States.
“We are pleased to collaborate with Xcellon Biologics, a leading CDMO company. By integrating IntoCell’s proprietary OHPAS linker and payload platforms with Xcellon’s bioconjugation and manufacturing expertise, we aim to provide global innovators with the tools and support necessary to bring differentiated ADC therapies to patients faster.”
Tae Kyo Park, CEO of IntoCell
Both companies stated that the partnership aligns with their shared mission to expand access to advanced ADC development capabilities and streamline the path from discovery to manufacturing.
